In Segment C, participants will receive ABBV-744 and oral navitoclax. In Section D, members will get ABBV-744 and ruxolitinib. Individuals will obtain treatment till condition progression or perhaps the members are not able to tolerate the study drugs. 88 These preclinical studies deliver paradigms for potential clinical trials in AML, https://clinical-effectiveness-of80134.activosblog.com/31237993/the-2-minute-rule-for-abbv-744-in-the-treatment-of-drug-resistant-cancers